INITIALL: Risk-based Pediatric Leukemia/Lymphoma Treatment
The standard treatment for acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LLy, a type of non‑Hodgkin lymphoma), and mixed phenotype acute leukemia/lymphoma (MPAL) is chemotherapy.
The risk-based pediatric leukemia/lymphoma study (INITIALL) aims to classify newly diagnosed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LLy), and mixed phenotype acute leukemia/lymphoma (MPAL) into low‑risk, standard‑risk, or high‑risk categories based on cytogenetic, molecular, and clinical features, so that subsequent therapy can be tailored accordingly.
Accurately determining the risk category of pediatric ALL, LLy, or MPAL is essential for optimizing treatment intensity, reducing toxicity, and improving overall survival while sparing children from unnecessary high‑intensity therapy.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Can natural killer cells cure leukemia?
- MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
- Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
- Immunotherapy for leukemia may change the bone marrow environment, cancer researchers find
- Next-generation CAR‑T therapy for acute myeloid leukemia: bridging innovation with clinical translation